Citi: Amgen (AMGN.US) diversified business growth offsets declining revenue from de-shu monoclonal antibody products; future prospects depend on execution of R&D pipeline

```htmlAccording to Golden Ten Data APP, after the U.S. stock market closed on Tuesday, November 3rd, Amgen (AMGN.US) announced its third-quarter 2026 results. The financial report shows that third-quarter revenue reached $10.365 billion, up 8% year-over-year and higher than the market's expected range of approximately $10.05—$10.07 billion. In terms of profit, non-GAAP earnings per share were $6.45, up 14% year-over-year and exceeding expectations of $5.77—$5.79; non-GAAP operating margin was 47.3%, an increase of 0.2 percentage points year-over-year; free cash flow was $3.7 billion (compared to $4.2 billion in the same period last year).```